Redeye expects a significant negative reaction of the stock in the magnitude of some -20% following today’s news. Once again, the issue was found in the high variability of Sprycel uptake in the group of fasting individuals. We will review the case following Xspray’s decision to go forward with its improved version, now called Dasynoc, and return later today with a more extensive comment regarding the path ahead.